Injective (INJ) Rallies on US Regulatory Talks and Bullish Signals
Injective (INJ) surged about 27%–30% to roughly $9.20–$9.35 on October 16, reaching its highest level since October 2025 and lifting its market capitalisation above $920 million. The rally followed a Washington meeting between Injective CEO Eric Chen and officials from the White House, the SEC and the CFTC. Injective said the discussion focused on advancing tokenisation within the US regulatory framework.
Other potential catalysts include a staker vote on IIP-709, a proposal for fixed gas fees, and Injective’s claim that its revenue-to-fully diluted valuation ratio compares favourably with other major chains. Institutional developments have also supported sentiment: Gulf Labs, a subsidiary of Thailand’s GULF Group, began operating a validator on Injective, while Canary Capital proposed a staked INJ ETF in the US. The ETF filing remains subject to regulatory review and is not an approval.
Technical indicators were broadly positive, with INJ trading above the Ichimoku Cloud, buyers in control on the Directional Movement Index and rising four-hour on-balance volume. Analyst Ali Martinez cited a cup-and-handle breakout and a potential target near $14. However, the rally appears stretched: the RSI approached 80 and the Commodity Channel Index exceeded 200, both warning of possible near-term consolidation. Traders are watching whether INJ can hold around $9, with resistance near $9.50 and potential targets at $10 and $10.50. Support is around $8.50–$8.70, followed by $7.85–$8.00. The regulatory meeting and institutional interest improve the outlook for Injective, but elevated momentum could mean sharp volatility or a pullback.
Bullish
The news is broadly bullish for INJ because the sharp price advance is accompanied by a meeting with US regulatory officials, institutional participation through a new validator, and a proposed staked INJ ETF. The reported technical breakout and positive trend indicators may attract momentum traders and support buying if INJ holds near $9 and clears resistance around $9.50.
The short-term risk is elevated. RSI near 80 and a Commodity Channel Index above 200 suggest the rally may be overextended, while traders may take profits after a 27%–30% move. A failure to hold $9 could bring the $8.50–$8.70 support zone into focus, with deeper support around $7.85–$8.00. Over the longer term, progress on US-compliant tokenisation and institutional engagement could strengthen demand for INJ, but neither the regulatory meeting nor the ETF proposal guarantees favourable outcomes. Overall, the catalysts support a positive bias, tempered by a meaningful risk of volatility and pullbacks.